The US Food and Drug Administration (FDA) has published its user fee rates for fiscal year 2025 across its prescription drug, generic drug, biosimilar, medical device, and over-the-counter monograph drug programs. The rates are calculated by factoring in its resources against the number of applications it expects to receive over the next fiscal cycle based on historical trends…
